Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
NCT07410559
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
189
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Imlunestrant + abemaciclib
DRUG:
(dd)EC*4-T*4
Sponsor
Fudan University